Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$816.65 USD
-12.78 (-1.54%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $816.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$816.65 USD
-12.78 (-1.54%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $816.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.
Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Down Y/Y
by Zacks Equity Research
Bayer AG's (BAYRY) fourth-quarter 2017 core earnings per share from continuing operations beat estimates.
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4
by Zacks Equity Research
Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.
Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down
by Zacks Equity Research
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Novavax (NVAX) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
The shares of Novavax (NVAX) rose over 8% yesterday.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Top Research Reports for Novo Nordisk, TJX Companies & Cigna
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), TJX Companies (TJX) and Cigna (CI).
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
by Zacks Equity Research
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Regeneron (REGN) Tops Q4 Earnings & Sales
by Ekta Bagri
Regeneron???s fourth-quarter 2017 earnings (excluding one-time charges) and sales topped expectations.
Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
by Zacks Equity Research
Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
Regeneron's Dupixent Receives MHLW Nod for Label Expansion
by Zacks Equity Research
Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
by Zacks Equity Research
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.